Influence of antipsychotics on mortality in schizophrenia: Systematic review

@article{Weinmann2009InfluenceOA,
  title={Influence of antipsychotics on mortality in schizophrenia: Systematic review},
  author={Stefan Weinmann and John Read and Volkmar Aderhold},
  journal={Schizophrenia Research},
  year={2009},
  volume={113},
  pages={1-11}
}

Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis

TLDR
A meta-analysis on a subgroup of four studies showed a consistent trend of an increased long-term mortality risk in schizophrenia patients who did not use antipsychotic medication during follow-up, favouring any exposure to antipsychotics.

Management of Schizophrenia in Late Life with Antipsychotic Medications

TLDR
Treatment of non-resistant, late-life schizophrenia with olanzapine and risperidone appears to be supported by the available evidence, however, data on geriatric patients with schizophrenia are generally scarce, particularly for treatment-resistant subpopulations, underscoring the need for more research in this important area.

Antipsychotic treatment and mortality in schizophrenia.

TLDR
Among patients with schizophrenia, the cumulative antipsychotic exposure displays a U-shaped curve for overall mortality, revealing the highest risk of death among those patients with no antipsychotics use.

Doubtful association of antipsychotic polypharmacy and high dosage with cognition in chronic schizophrenia

Maintenance treatment with antipsychotic drugs for schizophrenia.

TLDR
The efficacy of antipsychotic drugs for maintenance treatment in schizophrenia was clear and the results of the primary outcome were robust in a number of subgroup, meta-regression and analyses.

Polypharmacy in schizophrenia

TLDR
This review summarizes the current state of evidence of combined antipsychotic treatment strategies and the augmentation of antipsychotics with mood stabilizers, antidepressants and experimental substances and concludes that rigorous data on combination therapy in schizophrenia are rare and further randomized controlled trials, naturalistic trials and head-to-head-trials are necessary.

All-Cause Mortality and Medication Risk Factors in Schizophrenia: A Prospective Cohort Study

TLDR
Patients with schizophrenia have higher mortality rates than normal controls and the type of antipsychotic and concomitant medication can affect mortality rates in schizophrenia.

Antipsychotic Polypharmacy in the Treatment of Patientswith Resistant Schizophrenia: A Descriptive Study

TLDR
The results of this study warrant more efforts to be implemented to recommend the most effective APP with least side effects.
...

References

SHOWING 1-10 OF 44 REFERENCES

Validation of polypharmacy process measures in inpatient schizophrenia care.

TLDR
Two schizophrenia polypharmacy performance measures are evaluated in a cohort of 1,075 consecutively recruited individuals with schizophrenia in seven psychiatric hospitals to assess the influence of combining antipsychotics and different classes of psychotropic drugs on treatment outcome.

Serious Cardiovascular Events and Mortality Among Patients with Schizophrenia

TLDR
Among patients with schizophrenia, cardiovascular risk was inversely associated with intensity of use of antipsychotic drugs, suggesting that the observed risks may not be due to a simple or direct effect of drugs.

Mortality in schizophrenia

TLDR
Receiving more than one antipsychotic concurrently was associated with reduced survival, in the face of little or no systematic evidence to justify the widespread use of antipsychotics, and over-cautious attitudes to the use of adjunctive anticholinergics may require re-evaluation.

Schizophrenia, neuroleptic medication and mortality

TLDR
There is an urgent need to ascertain whether the high mortality in schizophrenia is attributable to the disorder itself or the antipsychotic medication.

Physical health and schizophrenia

TLDR
It is suggested that clinicians routinely assess and monitor physical health needs of patients with serious mental illness, as well as the cause of high rates of physical illness appears to be multifactorial involving shared vulnerability and genetic factors.

Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study

Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study

TLDR
Patients treated with perphenazine depot, clozapine, or olanzapine have a substantially lower risk of rehospitalisation or discontinuation of their initial treatment than do patients treated with haloperidol, and the effectiveness of first and second generation antipsychotics varies greatly in the community.

Second-Generation Antipsychotic Exposure and Metabolic-Related Disorders in Patients With Schizophrenia: An Observational Pharmacoepidemiology Study From 1988 to 2002

TLDR
After the introduction of SGAs, patients with schizophrenia in the United States have experienced a striking net increase in the prevalence of obesity and diabetes mellitus, likely to significantly add to an already elevated risk for cardiovascular disease in this population.

Atypical antipsychotic drugs and the risk of sudden cardiac death.

TLDR
Current users of typical and of atypical antipsychotic drugs had a similar, dose-related increased risk of sudden cardiac death.

A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?

TLDR
In light of the potential for second-generation antipsychotic medications to further adversely influence mortality rates in the decades to come, optimizing the general health of people with schizophrenia warrants urgent attention.